Full Breakdown
Investment Insights: Non-Tech Stocks in Focus for 2025
10/23/2025, 12:47:09 PM
Overview of Non-Tech Stocks Held by Leading Fund Managers
In 2025, a selection of non-tech stocks has garnered significant attention from top fund managers, reflecting their strategic investment choices amidst evolving market conditions. Eight funds, each holding 50 or fewer stocks and rated by Morningstar analysts as Gold, Silver, or Bronze, highlighted five key non-tech stocks with substantial cumulative weightings in their portfolios. Notably, these stocks include Eli Lilly, JPMorgan Chase, Stryker, UnitedHealth Group, and HCA Healthcare.
Eli Lilly: A Leader in Pharmaceuticals
Eli Lilly has gained prominence due to its drug tirzepatide, marketed as Mounjaro or Zepbound, which accounted for 37% of its sales in 2024 and is projected to rise to 50% in 2025. Analysts emphasize Lilly's strong position in treating obesity and type 2 diabetes, bolstered by its robust insulin production, which is less susceptible to generic competition. Despite a 11.2% decline in stock price over the past year, the company maintains a two-star rating, trading at a 26% premium to its fair value estimate.
JPMorgan Chase: Dominance in Financial Services
JPMorgan Chase, described as a dominant force in the U.S. banking sector, has seen its stock rise by 36.1% over the past year. Analysts highlight its diversified operations across investment banking, commercial banking, and asset management, contributing to its strong market position. The bank holds a two-star rating and trades at a 27% premium to its fair value estimate, reflecting confidence in its management and operational excellence.
Stryker: Strength in Medical Devices
Stryker, a medical device manufacturer, is recognized for its strong market position in orthopedic products and surgical robots. Analysts note that Stryker's extensive patent portfolio and effective sales strategies provide a competitive edge, particularly as it gains market share in surgical robotics. The stock is a significant holding in various funds, with a 5.7% weighting in the Jensen Quality Growth Fund.
UnitedHealth Group vs. Humana: A Healthcare Duel
UnitedHealth Group and Humana are two major players in the healthcare insurance market, each with distinct strengths. UnitedHealth, with a market capitalization of $330.1 billion, benefits from its diversified operations, including Optum, which provides healthcare services and analytics. However, it faces scrutiny over its Medicare billing practices and rising medical costs, leading to a 27.8% decline in stock price year-to-date.
Conversely, Humana, valued at $34.2 billion, has focused on Medicare Advantage plans and is showing signs of stabilization with improved cost discipline. Analysts project a 5.2% growth in earnings for Humana in 2025, contrasting with a steep decline anticipated for UnitedHealth. This divergence highlights Humana's potential as a more agile player in the evolving healthcare landscape.
HCA Healthcare: Navigating Challenges
HCA Healthcare, with a market cap of $101.1 billion, is positioned for long-term growth despite facing operational challenges. The company has effectively managed labor costs and diversified its supply chain to mitigate potential tariff impacts. Analysts project a moderate trading range for HCA, with a bullish outlook for 2030, reflecting confidence in its operational model and ability to capture market demand.
Conclusion: Strategic Insights for Investors
As 2025 unfolds, these non-tech stocks present diverse opportunities for investors. While Eli Lilly, JPMorgan Chase, Stryker, UnitedHealth Group, and HCA Healthcare each face unique challenges and growth prospects, their strategic positioning within their respective industries underscores their potential as key investment choices. Investors are advised to consider these dynamics carefully when evaluating their portfolios.
